Claudia Bockstiegel - Roche Holding G Counsel

All Insiders . USA . 
Stock . Roche Holding AG . Stakeholders . Insider . Claudia Bockstiegel
RHHBF Stock  USD 306.98  4.06  1.34%   

Insider

Claudia Bockstiegel is G Counsel of Roche Holding AG
Age 59
Phone41 61 688 11 11
Webhttps://www.roche.com

Roche Holding Management Efficiency

The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.
Roche Holding AG has accumulated 16.08 B in total debt with debt to equity ratio (D/E) of 1.0, which is about average as compared to similar companies. Roche Holding AG has a current ratio of 1.09, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Roche Holding until it has trouble settling it off, either with new capital or with free cash flow. So, Roche Holding's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Roche Holding AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Roche to invest in growth at high rates of return. When we think about Roche Holding's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

William CarapezziPfizer Inc
63
Mike McdermottPfizer Inc
N/A
Virginia BouletLumen Technologies
66
Spencer RascoffPalantir Technologies Class
44
Kamran CheemaAkoustis Technologies
51
Christopher LapointeSoFi Technologies
40
Alexander MoorePalantir Technologies Class
37
Michael RobertsLumen Technologies
70
Quincy AllenLumen Technologies
60
Nuria LapeaGrifols SA ADR
60
Kenneth BollerAkoustis Technologies
53
Stacey GoffLumen Technologies
58
Rodney NelsonPalantir Technologies Class
N/A
Montserrat LlamasGrifols SA ADR
59
Kevin ChiltonLumen Technologies
65
Steven JDGrifols SA ADR
64
Anna AvalosSoFi Technologies
N/A
Matthew LongPalantir Technologies Class
39
Aamir MalikPfizer Inc
48
George HuttonSoFi Technologies
68
Gordon LohPfizer Inc
N/A
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company was founded in 1896 and is headquartered in Basel, Switzerland. ROCHE HOLDINGS operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 100920 people. Roche Holding AG [RHHBF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity0.45
Return On Asset0.15

Roche Holding AG Leadership Team

Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications
Claudia Bockstiegel, G Counsel
Bruno Eschli, Head Relations
Johannes MD, Head Devel
Thomas Schinecker, Chief Diagnostics
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals
Alan Hippe, CFO and IT Officer
Severin Schwan, CEO and Director
Pascale Schmidt, Chief Officer

Roche Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.45
Return On Asset0.15
Profit Margin0.19 %
Operating Margin0.32 %
Current Valuation287.91 B
Shares Outstanding106.69 M
Shares Owned By Insiders75.31 %
Shares Owned By Institutions8.56 %
Price To Earning21.63 X
Price To Book11.61 X

Currently Active Assets on Macroaxis

ESRTEmpire State Realty
CCitigroup
CCitigroup
GOOGAlphabet Inc Class C
DDDupont De Nemours

Other Information on Investing in Roche OTC Stock

Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY